Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07227948 · ClinicalTrials.gov registry record · Phase 2

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

A Phase 2 study of Cocaine Use Disorder, sponsored by The University of Texas Health Science Center, Houston.

Recruiting
Registry status
Phase 2
Development phase
75
Enrollment target
1
Study location

NCT07227948: Recruiting Phase 2 study of Cocaine Use Disorder, sponsored by The University of Texas Health Science Center, Houston.

NCT07227948 is a Phase 2 study of Cocaine Use Disorder that is actively recruiting participants, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 75 participants, below the 101-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07227948, a Phase 2 study of Cocaine Use Disorder, is actively recruiting participants, sponsored by The University of Texas Health Science Center, Houston.

RECRUITING
Registry status
Phase 2
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to evaluate semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in combination with cognitive behavioral therapy (CBT) for the treatment of cocaine use disorder (CUD). This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/).

Primary Outcome

EEG will be recorded during a passive picture viewing presentation that will include cocaine-related, neutral, and nondrug-related pleasant and unpleasant images. For each participant, the amplitude of the LPP component will be calculated separately for each picture category and used to evaluate the motivational relevance of the images.LPP amplitude reflects the motivational relevance of visual stimuli, with larger amplitudes indicating greater motivational salience.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Semaglutide
  • BEHAVIORAL cognitive behavioral therapy (CBT).

Study Locations (1)

Texas

  • The University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2026-01-15
Est. Completion 2029-02-28
Phase Phase 2

What NCT07227948 shows while recruiting

NCT07227948 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 101-participant average among 26 other Cocaine Use Disorder trials with a reported enrollment target (26% lower).

The record links to 1 condition, with Cocaine Use Disorder appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT07227948 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT07227948 about?

NCT07227948 is a clinical study titled "Repurposing Semaglutide for the Treatment of Cocaine Use Disorder". The purpose of this study is to evaluate semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in combination with cognitive behavioral therapy (CBT) for the treatment of cocaine use disorder (CUD). This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (ht...

What is the current status of trial NCT07227948?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2026-01-15. Estimated completion is 2029-02-28.

What conditions does trial NCT07227948 study?

This clinical trial studies the following conditions: Cocaine Use Disorder.

What interventions are being tested in trial NCT07227948?

The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), cognitive behavioral therapy (CBT). (BEHAVIORAL).

Who is sponsoring clinical trial NCT07227948?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07227948 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cocaine Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07227948's enrollment target sits among peer trials

75 11th of 26 higher than 15 of 26 other Cocaine Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cocaine Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07227948, the US trial registry maintained by the National Library of Medicine. NCT07227948 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.